Company Research Report: Contraline, Inc.

Company Overview

• Name: Contraline, Inc.

• Mission: Contraline is dedicated to inventing the future of male contraception, aiming to provide men and couples with long-lasting, safe, effective, and reversible contraception that fits seamlessly into people's lives.

• Founded Date & Founders: Founded in 2015 by Kevin Eisenfrats and Dr. John Herr.

• Key People:

• Kevin Eisenfrats, Co-Founder & CEO

• Dr. John Herr, Co-Founder

• Dr. Alexander Pastuszak, Chief Medical Officer

• Headquarters: 818 E. Jefferson St. Suite 201, Charlottesville, VA 22902, USA.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Contraline is known for developing ADAM™, the world’s first implant designed to provide men with long-lasting contraception, akin to an IUD, but for men.

Products

ADAM™

• Description: ADAM™ is an investigational hydrogel implant designed to provide long-lasting, non-hormonal, and non-permanent male contraception.

• Key Features:

• Designed for Peace of Mind: The hydrogel implant is a "set and forget" solution.

• Non-Hormonal: Avoids systemic side-effects associated with hormonal methods.

• Quick and Minimally Invasive Procedure: The implantation procedure is simple and can be done on an outpatient basis.

• Reversible and Non-Permanent: Unlike vasectomies, the implant is designed to be reversible.

• At-Home Monitoring: Allows users to conduct home sperm checks to verify its effectiveness.

Recent Developments

• Clinical Trial Enrollment: As of 2022, the First-in-Human clinical trial of the ADAM device is ongoing in Australia, with the first patients having been successfully implanted and showing 12 months of efficacy.

• Trial Expansion: Recently expanded clinical trial sites in Australia include South Coast Urology in Wollongong and AndroUrology Centre in Brisbane.

• Collaborations: Partnered with DNA Diagnostics Center to integrate SpermCheck Vasectomy for real-time monitoring of contraceptive efficacy during trials.

• Promising Trial Results: Initial outcomes have demonstrated the safety and efficacy of the ADAM system with significant reduction in sperm motility and no serious adverse events reported.

• Partnerships: Entered an Option-to-License Agreement with the Population Council.

• Market Potential: A large number of men have expressed interest in a viable male contraceptive, with over 1,500 signing up for clinical trials and market research indicating strong preference for long-term male contraceptive options.

This report has covered the available information about Contraline, Inc., its mission, and its groundbreaking product, ADAM™. The focus on reproductive equity and the recent advancements in clinical trials position Contraline at the forefront of male contraceptive innovation.